Interplay between *Helicobacter pylori* Infection, Interleukin-11, and Leukemia Inhibitory Factor in Gastric Cancer among Egyptian Patients

Dina Sabry, 1 Omayma O. Abdelaleem, 1 Enas M. Hefzy, 2 **Amal A. Ibrahim, 2** Tarek I. Ahmed, 3 Essam A. Hassan, 4 Nehal D. Abdel-Hameed, 5 and Mahmoud A.F. Khaliló 1 Departments of Medical Biochemistry and Molecular Biology, 5 Clinical Pathology, Faculty of

Medicine, Cairo University, Cairo, Egypt. 2 Departments of Medical Microbiology and Immunology,

3 Internal Medicine, 4 Tropical Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt. 6

Department of Microbiology and Immunology, Faculty of Pharmacy, Fayoum University, Fayoum,

Egypt.

Type of research: Joint research

Published in: Journal of Interferon and Cytokine Research, Volume 38, Number 11,

2018

Abstract

Helicobacter pylori is a ubiquitous Gram-negative bacterium that is responsible for gastric mucosal inflammation. It is the most common risk factor for gastric cancer (GC). The current study aimed to investigate the association between interleukin-11 (IL-11) and leukemia inhibitory factor (LIF) levels among H. pylori-infected Egyptian patients with gastritis and GC. One hundred forty-seven patients with gastric lesions were endoscopically biopsied and assessed using rapid urease test and immunohistochemistry. Quantitative real-time polymerase chain reaction was done for the detection of *H. pylori* load in gastric biopsies and detection of LIF as well as IL-11 relative gene expression. The mean values of *H. pylori* load, LIF, and IL-11 were significantly elevated in GC patients compared to gastritis group (P < 0.0001). A positive significant correlation was detected between mucosal levels of LIF, IL-11, and H. pylori load in both groups. Both LIF and IL-11 had the same pattern of expression in gastric tissues with different types of gastritis and different types and grades of gastric carcinoma. This report could clarify the molecular events associated with the immune response against H. pylori infection and H. pylori-associated pathology. Therefore, development of immunotherapy strategies against H. pylori-induced cytokines becomes inevitable.